Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis
- PMID: 24708441
- PMCID: PMC4201939
- DOI: 10.1111/jdv.12296
Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis
Abstract
Background: Psoriasis may predispose to cardiovascular disease and diabetes. However, the role of tumor necrosis factor (TNF) inhibitor in mediating this risk is controversial.
Objective: To assess this relationship, we estimated change in metabolic physiologic measures before and after initiation of TNF inhibitor therapy compared with methotrexate (MTX) therapy among psoriasis patients.
Methods: We conducted a retrospective cohort study, 2007-2012, using computerized clinical data for 1274 new users of TNF inhibitor and 979 new users of MTX therapy to compare change in blood pressure, lipids, triglycerides, fasting plasma glucose and body mass index (BMI) before and after start of TNF inhibitors or MTX. The study was restricted to new users. We computed within-person change in each measure, so that each patient served as their own control. In addition, we compared TNF inhibitor patients to MTX patients, by computing the adjusted difference in their group means. In secondary analyses, we examined phototherapy as a comparator.
Results: Among starters of TNF inhibitor and MTX therapy, within-person change in physiologic measures at 6 months did not differ significantly. We observed no important or significant changes in any of the physiologic measures with initiation of TNF inhibitor compared with MTX. The same results were found in subgroup analyses focused on men, and on those with hypertension, diabetes mellitus, or obesity. The same results were observed with phototherapy, except that diastolic blood pressure declined by 0.6 mmHg within person during the 6 months after starting phototherapy (P < 0.05).
Conclusions: The study provides no evidence for improvement of physiologic measures associated with the metabolic syndrome resulting from TNF inhibitor use for psoriasis.
© 2013 European Academy of Dermatology and Venereology.
Conflict of interest statement
The other co-authors do not have any disclosures.
Figures
Similar articles
-
The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study.J Dermatolog Treat. 2018 Feb;29(1):3-7. doi: 10.1080/09546634.2016.1254145. Epub 2017 Nov 17. J Dermatolog Treat. 2018. PMID: 27881030
-
Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4. doi: 10.1111/j.1468-3083.2007.02429.x. Epub 2007 Nov 14. J Eur Acad Dermatol Venereol. 2008. PMID: 18005022
-
No association between TNF inhibitor and methotrexate therapy versus methotrexate in changes in hemoglobin A1C and fasting glucose among psoriasis, psoriatic arthritis, and rheumatoid arthritis patients.J Drugs Dermatol. 2015 Feb;14(2):159-66. J Drugs Dermatol. 2015. PMID: 25689811
-
From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.J Am Acad Dermatol. 2014 Jan;70(1):168-77. doi: 10.1016/j.jaad.2013.09.020. Epub 2013 Nov 1. J Am Acad Dermatol. 2014. PMID: 24184141 Review.
-
Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment.Cutis. 2013 Sep;92(3):140-7. Cutis. 2013. PMID: 24153143 Review.
Cited by
-
Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome.Postepy Dermatol Alergol. 2019 Feb;36(1):70-75. doi: 10.5114/ada.2018.73136. Epub 2019 Feb 2. Postepy Dermatol Alergol. 2019. PMID: 30858782 Free PMC article.
-
Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis.Front Immunol. 2024 Mar 4;15:1354593. doi: 10.3389/fimmu.2024.1354593. eCollection 2024. Front Immunol. 2024. PMID: 38500874 Free PMC article.
-
Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis.Front Pharmacol. 2020 Apr 15;11:481. doi: 10.3389/fphar.2020.00481. eCollection 2020. Front Pharmacol. 2020. PMID: 32351392 Free PMC article.
References
-
- Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011 Aug;270(2):147–157. - PubMed
-
- Ahlehoff O, Gislason GH, Jørgensen CH, Lindhardsen J, Charlot M, Olesen JB, Abildstrøm SZ, Skov L, Torp-Pedersen C, Hansen PR. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J. 2012 Aug;33(16):2054–2064. - PubMed
-
- Wakkee M, Meijer W, Neumann HA, Herings RM, Nijsten T. Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study. Acta Derm Venereol. 2009;89(5):476–483. - PubMed
-
- Wakkee M, Herings RM, Nijsten T. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol. 2010 Apr;130(4):962–967. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical